Abstract
We report the use of steroid-based compounds as probes for the active site of 17β-hydroxysteroid dehydrogenase, in particular, type 3 (17β-HSD3). Results suggest that the compounds were good inhibitors of 17β-HSD3 – a number were extremely potent with respect to the standard compounds used.
Keywords: 17β-hydroxysteroid dehydrogenase, Type 3, Inhibition, Enzyme, Steroid-based compound
Letters in Drug Design & Discovery
Title: Esters of Dehydroepiandrosterone (DHEA) as Probes for the Active Site of Type 3 17β-Hydroxysteroid Dehydrogenase (17β-HSD3)
Volume: 7 Issue: 5
Author(s): Moniola S. Olusanjo, Caroline P. Owen and Sabbir Ahmed
Affiliation:
Keywords: 17β-hydroxysteroid dehydrogenase, Type 3, Inhibition, Enzyme, Steroid-based compound
Abstract: We report the use of steroid-based compounds as probes for the active site of 17β-hydroxysteroid dehydrogenase, in particular, type 3 (17β-HSD3). Results suggest that the compounds were good inhibitors of 17β-HSD3 – a number were extremely potent with respect to the standard compounds used.
Export Options
About this article
Cite this article as:
S. Olusanjo Moniola, P. Owen Caroline and Ahmed Sabbir, Esters of Dehydroepiandrosterone (DHEA) as Probes for the Active Site of Type 3 17β-Hydroxysteroid Dehydrogenase (17β-HSD3), Letters in Drug Design & Discovery 2010; 7 (5) . https://dx.doi.org/10.2174/157018010791163505
DOI https://dx.doi.org/10.2174/157018010791163505 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiangiogenic Therapy
Current Pharmaceutical Design Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery Recent Technological Advances in the Mass Spectrometry-based Nanomedicine Studies: An Insight from Nanoproteomics
Current Pharmaceutical Design An Update of In Silico Tools for the Prediction of Pathogenesis in Missense Variants
Current Bioinformatics Meet Our Editorial Board Member
Current Clinical Pharmacology mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches
Current Drug Metabolism Aurones as New Porcine Pancreatic α-Amylase Inhibitors
Letters in Drug Design & Discovery Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism Optimizing Anti-EGFR Strategies in Cancer Treatment
Current Cancer Therapy Reviews Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery